

Thrombocytopathy and endotheliopathy: crucial contributors to thromboinflammation

Nature Reviews Cardiology

18, 194-209

DOI: [10.1038/s41569-020-00469-1](https://doi.org/10.1038/s41569-020-00469-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Hematologic disorders associated with COVID-19: a review. <i>Annals of Hematology</i> , 2021, 100, 309-320.	0.8	62
2	Reply to: Autonomic dyshomeostasis in patients with diabetes mellitus during COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 189-190.	4.3	2
3	COVID-19-associated thrombotic microangiopathy (TMA). <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 307-314.	0.1	0
4	Roborovski hamster <i>Phodopus roborovskii</i> strain SH101 as a systemic infection model of SARS-CoV-2. <i>Virulence</i> , 2021, 12, 2430-2442.	1.8	16
5	The Role of TEG Analysis in Patients with COVID-19-Associated Coagulopathy: A Systematic Review. <i>Diagnostics</i> , 2021, 11, 172.	1.3	49
6	Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. <i>Reviews in Medical Virology</i> , 2021, 31, 1-13.	3.9	40
7	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. <i>Expert Review of Proteomics</i> , 2021, 18, 105-118.	1.3	10
8	Thrombocytopathies: Not Just Aggregation Defects—The Clinical Relevance of Procoagulant Platelets. <i>Journal of Clinical Medicine</i> , 2021, 10, 894.	1.0	15
10	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2356.	1.8	13
11	Elevated P-Selectin in Severe Covid-19: Considerations for therapeutic options. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021016.	0.5	28
13	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
14	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100088.	7.8	60
15	Acute Limb Ischemia as the Initial Severe Presentation in COVID-19. <i>Cureus</i> , 2021, 13, e14226.	0.2	1
17	Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. <i>Infection</i> , 2021, 49, 725-737.	2.3	14
19	Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 124-129.	1.0	28
21	Platelet Function in Viral Immunity and SARS-CoV-2 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 419-426.	1.5	14
22	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	10.6	594
23	ST-segment elevation myocardial infarction in post-COVID-19 patients: A case series. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 425-430.	0.2	18

#	ARTICLE	IF	CITATIONS
24	Single-nucleus transcriptomic landscape of primate hippocampal aging. <i>Protein and Cell</i> , 2021, 12, 695-716.	4.8	49
25	Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. <i>PLoS Medicine</i> , 2021, 18, e1003648.	3.9	39
26	COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury. <i>American Journal of Pathology</i> , 2021, 191, 1374-1384.	1.9	78
27	Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome. <i>International Journal of Infectious Diseases</i> , 2021, 106, 300-301.	1.5	1
28	Lessons learnt from COVID-19 coagulopathy. <i>EJHaem</i> , 2021, 2, 577-584.	0.4	12
30	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. <i>Intensive Care Medicine</i> , 2021, 47, 899-902.	3.9	38
31	COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit? An Insight from the GeroCovid Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 105-112.	1.8	21
32	Machine Learning to Predict In-Hospital Mortality in COVID-19 Patients Using Computed Tomography-Derived Pulmonary and Vascular Features. <i>Journal of Personalized Medicine</i> , 2021, 11, 501.	1.1	21
33	Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study. <i>Thrombosis Research</i> , 2021, 202, 17-23.	0.8	41
35	Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2080-2096.	1.1	21
36	COVID-19: a pandemic challenging healthcare systems. <i>IJSE Transactions on Healthcare Systems Engineering</i> , 0, , 1-22.	1.2	1
37	Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 746-753.	1.0	2
38	The Right Ventricle in COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2535.	1.0	21
40	Pathogenesis of hemorrhagic disease caused by elephant endotheliotropic herpesvirus (EEHV) in Asian elephants (<i>Elephas maximus</i>). <i>Scientific Reports</i> , 2021, 11, 12998.	1.6	12
41	Predictors of Worsening Oxygenation in COVID-19. <i>Tuberculosis and Respiratory Diseases</i> , 2021, 84, 250-251.	0.7	1
42	Surgical thrombectomy versus conservative treatment in cases of acute limb ischemia with COVID-19 pneumonia. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2885.	0.4	4
43	Persistent Symptoms and Disability After COVID-19 Hospitalization: Data From a Comprehensive Telerehabilitation Program. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 1308-1316.	0.5	36
44	Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. <i>Pharmaceuticals</i> , 2021, 14, 751.	1.7	13

#	ARTICLE	IF	CITATIONS
45	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28
46	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7942.	1.8	20
47	The Many Faces of JAKs and STATs Within the COVID-19 Storm. <i>Frontiers in Immunology</i> , 2021, 12, 690477.	2.2	18
48	Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	66
49	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1261-1261.	0.7	3
50	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1105-1107.	0.5	12
51	Altered platelet and coagulation function in moderate-to-severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 16290.	1.6	24
52	Thrombocytopenia in COVID-19: Focused Summary of Current Understanding of Mechanisms and Clinical Implications. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 243-248.	0.3	3
53	C-C motive chemokine ligand 2 and thromboinflammation in COVID-19-associated pneumonia: A retrospective study. <i>Thrombosis Research</i> , 2021, 204, 88-94.	0.8	5
54	On the prevention and treatment of Alzheimer's disease: Control the promoters and look beyond the brain. <i>Medical Hypotheses</i> , 2021, 154, 110645.	0.8	2
55	Scratching the Surface. <i>Advances in Anesthesia</i> , 2021, 39, 35-51.	0.5	5
56	Platelets amplify endotheliopathy in COVID-19. <i>Science Advances</i> , 2021, 7, eabh2434.	4.7	78
57	The Prognostic Value of ADAMTS-13 and von Willebrand Factor in COVID-19 Patients: Prospective Evaluation by Care Setting. <i>Diagnostics</i> , 2021, 11, 1648.	1.3	6
58	Change in platelet indices in patients with Coronavirus disease-2019 (COVID-19): A reflection of platelet activation and contribution to immunothrombosis?. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	3
60	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. <i>Journal of Hepatology</i> , 2021, 75, 647-658.	1.8	67
61	Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?. <i>Frontiers in Medicine</i> , 2021, 8, 718053.	1.2	7
62	Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 111, 211-218.	1.5	29
63	Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154845.	1.5	22

#	ARTICLE	IF	CITATIONS
64	Lung Function and Symptoms in Post-COVID-19 Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 907-915.	1.2	16
65	ACEi reduces hypertension-induced hyperinflammation in COVID-19. <i>Nature Reviews Cardiology</i> , 2021, 18, 231-231.	6.1	1
66	Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. <i>Theranostics</i> , 2021, 11, 8234-8253.	4.6	16
67	Endothelial cell infection and dysfunction, immune activation in severe COVID-19. <i>Theranostics</i> , 2021, 11, 8076-8091.	4.6	70
69	Endothelial cells are not productively infected by SARS-CoV-2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1350.	1.7	88
70	Roles of Interleukin-17 and Th17 Responses in COVID-19. <i>Journal of Bacteriology and Virology</i> , 2021, 51, 89-102.	0.0	4
71	Coagulopathy and COVID-19. <i>European Heart Journal Supplements</i> , 2021, 23, E95-E98.	0.0	18
72	The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. <i>Biomolecules</i> , 2021, 11, 1558.	1.8	1
73	A review of ischemic stroke in COVID-19: currently known pathophysiological mechanisms. <i>Neurological Sciences</i> , 2022, 43, 67-79.	0.9	16
74	Molecular mechanisms of vasculopathy and coagulopathy in COVID-19. <i>Biological Chemistry</i> , 2021, 402, 1505-1518.	1.2	10
75	Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10791.	1.8	20
77	Platelets and COVID-19. <i>Hamostaseologie</i> , 2021, 41, 379-385.	0.9	47
78	Establishment of prediction models for COVID-19 patients in different age groups based on random Forest algorithm. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.2	6
79	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 17-31.	1.9	45
80	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. <i>International Journal of Cardiology</i> , 2021, 344, 240-245.	0.8	17
81	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4925.	1.0	27
82	Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. <i>Thrombosis Research</i> , 2021, 208, 4-10.	0.8	14
83	Clinical Features and Management of COVID-19 Associated Hypercoagulability. <i>Cardiac Electrophysiology Clinics</i> , 2021, 14, 41-52.	0.7	2

#	ARTICLE	IF	CITATIONS
84	COVID-19-associated Endothelial Dysfunction and Microvascular Injury. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 21-28.	0.7	9
85	Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1289-1297.	1.0	7
86	Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2022, 347, 89-96.	0.8	37
87	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
89	A fresh look at coronary microembolization. <i>Nature Reviews Cardiology</i> , 2022, 19, 265-280.	6.1	56
90	Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19. <i>Biology</i> , 2021, 10, 1186.	1.3	10
91	Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 767291.	1.2	3
92	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 307-313.	1.3	12
93	Thrombocytopenia vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications. <i>Platelets</i> , 2021, , 1-6.	1.1	3
94	A un año de la pandemia en Argentina, características clínicas de pacientes con accidente cerebrovascular agudo en una cohorte hospitalaria y sus implicancias. <i>Neurología Argentina</i> , 2021, , .	0.1	0
95	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	2.0	41
96	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
97	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 792335.	1.8	3
98	Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation. <i>Frontiers in Immunology</i> , 2022, 13, 847894.	2.2	21
99	Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications. <i>World Journal of Clinical Cases</i> , 2022, 10, 762-776.	0.3	12
100	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784505.	1.8	5
101	Hyperglycemia, Reduced Hematopoietic Stem Cells, and Outcome of COVID-19. <i>Diabetes</i> , 2022, 71, 788-794.	0.3	8
102	Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients. <i>Journal of Molecular Medicine</i> , 2022, 100, 569-584.	1.7	12

#	ARTICLE	IF	CITATIONS
103	Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes. <i>Journal of Pathology</i> , 2022, 257, 198-217.	2.1	16
104	Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. , 2022, 235, 108121.		20
105	Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury. <i>Frontiers in Immunology</i> , 2022, 13, 776861.	2.2	12
106	Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches. <i>Reviews in Medical Virology</i> , 2022, 32, e2334.	3.9	24
107	Low Dose Chronic Angiotensin II Induces Selective Senescence of Kidney Endothelial Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 782841.	1.8	8
108	COVID-19 Pulmonary and Extrapulmonary Complications. <i>Journal of Biosciences and Medicines</i> , 2022, 10, 152-174.	0.1	0
109	Rotational Thromboelastometry Profile among Critically ill COVID-19 Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210912.	0.7	0
110	Thrombocytopenia and COVID-19: Differential diagnosis and therapy. <i>Srpski Medicinski Åasopis Lekarske Komore</i> , 2022, 3, 87-99.	0.1	0
111	Adipose tissue in COVID-19: detection of SARS-CoV-2 in adipocytes and activation of the interferon-alpha response. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1021-1029.	1.8	33
112	The Spectrum of Acute Cerebrovascular Disease in Patients with COVID-19. <i>Biomedicines</i> , 2022, 10, 435.	1.4	1
113	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 824851.	1.8	51
114	Inhaled iloprost can improve oxygenation and shunt fraction in severe COVID-19. <i>Acute and Critical Care</i> , 2022, 37, 127-130.	0.6	0
115	Network pharmacology-based predictions of active components and pharmacological mechanisms of <i>Artemisia annua</i> L. for the treatment of the novel Corona virus disease 2019 (COVID-19). <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 56.	1.2	12
116	A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. , 2022, 1, 223-237.		20
117	Obesity and COVID-19: Mechanistic Insights From Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1799-1811.	1.8	17
118	When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1315-1332.	0.8	5
119	COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. <i>International Journal of Hematology</i> , 2022, 115, 457-469.	0.7	18
120	Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy. <i>Metabolites</i> , 2022, 12, 240.	1.3	16

#	ARTICLE	IF	CITATIONS
121	The pathological maelstrom of COVID-19 and cardiovascular disease. , 2022, 1, 200-210.		14
122	Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. <i>Life</i> , 2022, 12, 478.	1.1	5
123	Endothelial Dysfunction in SARS-CoV-2 Infection. <i>Biomedicines</i> , 2022, 10, 654.	1.4	6
124	Activated Platelets Upregulate β_2 Integrin Mac-1 (CD11b/CD18) on Dendritic Cells, Which Mediates Heterotypic Cell-Cell Interaction. <i>Journal of Immunology</i> , 2022, 208, 1729-1741.	0.4	7
125	International Prevalence and Mechanisms of SARS-CoV-2 in Childhood Arterial Ischemic Stroke During the COVID-19 Pandemic. <i>Stroke</i> , 2022, 53, 2497-2503.	1.0	13
126	HIV-associated thrombotic thrombocytopenic purpura (HIV-aTTP): A practical guide and review of the literature. <i>HIV Medicine</i> , 2022, 23, 1033-1040.	1.0	2
127	Morphological and Immunopathological Aspects of Lingual Tissues in COVID-19. <i>Cells</i> , 2022, 11, 1248.	1.8	11
128	COVID-19 Presenting With a Challenging Combination of Thrombocytopenia and Thrombosis. <i>Journal of Medical Cases</i> , 2022, 13, 168-171.	0.4	0
129	Long-term outcomes of pediatric infections: from traditional infectious diseases to long Covid. <i>Future Microbiology</i> , 2022, 17, 551-571.	1.0	62
130	Peculiarities of blood coagulation disorders in patients with COVID-19. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1255-1263.	0.2	0
131	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.4	56
133	COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management. <i>Journal of Personalized Medicine</i> , 2021, 11, 1328.	1.1	6
134	Platelet Dysregulation in the Pathobiology of COVID-19. <i>Hamostaseologie</i> , 2021, , .	0.9	2
135	Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. <i>Pathobiology</i> , 2022, 89, 166-177.	1.9	4
136	Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 70.	1.0	16
138	Fibrinolytic therapy for COVID-19: a review of case series. <i>Acta Pharmacologica Sinica</i> , 2021, , .	2.8	3
139	Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 7135.	5.8	40
140	Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland. <i>Journal of Clinical Medicine</i> , 2022, 11, 117.	1.0	18

#	ARTICLE	IF	CITATIONS
141	Binding of phosphatidylserineâ€positive microparticles by PBMCs classifies disease severity in COVIDâ€19 patients. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12173.	5.5	19
142	Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating <i>in-silico</i> approach. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
143	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 817-822.	0.7	3
145	The Relationship of Vitamin D Deficiency and Obesity with Coronavirus Disease Infection. , 2022, 5, 76-84.		0
146	Is there any association between plasma lipid profile and severity of COVID-19?. <i>Clinical Nutrition ESPEN</i> , 2022, , .	0.5	1
147	Long-term mortality following SARS-CoV-2 infection: A national cohort study from Estonia. <i>Lancet Regional Health - Europe</i> , The, 2022, 18, 100394.	3.0	22
148	Late onset ST-elevation myocardial infarction (STEMI) in patient with COVID-19: A case report from Nepal. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103764.	0.5	2
149	The microfluidic artificial lung: Mimicking nature's blood path design to solve the biocompatibility paradox. <i>Artificial Organs</i> , 2022, 46, 1227-1239.	1.0	7
150	Thrombosis-Related DNA Polymorphisms. , 0, , .		0
151	Mechanisms of Cardiovascular System Injury Induced by COVID-19 in Elderly Patients With Cardiovascular History. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	1
152	ENDOTHELIAL BIOMARKERS IN PATIENTS RECOVERED FROM COVID-19 ONE YEAR AFTER HOSPITAL DISCHARGE: A CROSS-SECTIONAL STUDY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022033.	0.5	10
153	The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland. <i>Environmental Pollution</i> , 2022, 306, 119469.	3.7	20
154	The role of platelets in antiviral immunity. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 204-212.	0.2	2
155	Microthrombosis as a cause of fulminant myocarditis-like presentation with COVID-19 proven by endomyocardial biopsy. <i>Cardiovascular Pathology</i> , 2022, 60, 107435.	0.7	5
156	Endothelial dysfunction and thrombotic events in patients with severe novel coronavirus infection COVID-19. <i>UÅenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova</i> , 2022, 28, 38-47.	0.0	3
157	Stroke in theÂCOVID-19 pandemic era. <i>Postepy Psychiatrii I Neurologii</i> , 2022, 31, 69-73.	0.2	1
158	Redox Mechanisms of Platelet Activation in Aging. <i>Antioxidants</i> , 2022, 11, 995.	2.2	4
159	An evaluation of the impact of the Coronavirus (COVID 19) pandemic on interventional radiographers' wellbeing. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, 384-395.	0.2	6

#	ARTICLE	IF	CITATIONS
160	Could a Lower Toll-like Receptor (TLR) and NF- κ B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5966.	1.8	9
161	Platelet Distribution Width and Increased D-Dimer at Admission Predicts Subsequent Development of ARDS in COVID-19 Patients. <i>Pathophysiology</i> , 2022, 29, 233-242.	1.0	2
163	Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
164	Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1403-1420.	0.8	10
165	Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
166	The Role of Host-Cellular Responses in COVID-19 Endothelial Dysfunction. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
167	A Hybrid Feature Selection Approach to Screen a Novel Set of Blood Biomarkers for Early COVID-19 Mortality Prediction. <i>Diagnostics</i> , 2022, 12, 1604.	1.3	5
168	Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 109-115.	1.3	26
169	CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	19
170	Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19. <i>Blood Advances</i> , 2022, 6, 3884-3898.	2.5	12
171	Platelet Count in Patients with SARS-CoV-2 Infection: A Prognostic Factor in COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 4112.	1.0	5
172	Paroxysmal Finger Hematoma—A Probable Vascular Disorder in Post-COVID-19 Condition: Two Clinical Case Presentations. <i>Medicina (Lithuania)</i> , 2022, 58, 915.	0.8	1
173	A practical treatment for COVID-19 and the next pandemic. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	9
174	The Role of Vascular-Platelet Hemostasis Disturbances in the Genesis of Respiratory Failure in Patients with COVID-19. <i>Messenger of Anesthesiology and Resuscitation</i> , 2022, 19, 15-24.	0.1	1
175	Oral antiviral treatments for COVID-19: opportunities and challenges. <i>Pharmacological Reports</i> , 2022, 74, 1255-1278.	1.5	31
176	Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey. <i>Pharmacological Research</i> , 2022, 183, 106360.	3.1	42
177	The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?. <i>Croatian Medical Journal</i> , 2022, 63, 287-294.	0.2	1
178	Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study. <i>Brain Communications</i> , 2022, 4, .	1.5	3

#	ARTICLE	IF	CITATIONS
179	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. <i>Neurotherapeutics</i> , 2022, 19, 1435-1466.	2.1	22
180	Human coronaviruses disassemble processing bodies. <i>PLoS Pathogens</i> , 2022, 18, e1010724.	2.1	9
181	The role of platelets, neutrophils and endothelium in COVID-19 infection. <i>Expert Review of Hematology</i> , 2022, 15, 727-745.	1.0	7
182	Prognostic value of proadrenomedullin in patients with COVID-19. <i>Meditinskiy Sovet</i> , 2022, , 200-205.	0.1	0
183	The prevalence of vascular complications in SARS-CoV-2 infected outpatients. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	2
184	A feedback loop between platelets and NETs amplifies inflammation in severe sepsis. , 2022, 1, 698-699.		1
185	Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine. <i>EPMA Journal</i> , 2022, 13, 407-431.	3.3	5
186	Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19. <i>RNA Biology</i> , 2022, 19, 963-979.	1.5	11
187	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
188	The Potential Impact of Heparanase Activity and Endothelial Damage in COVID-19 Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 5261.	1.0	2
189	Ischemic and hemorrhagic abdominal complications in COVID-19 patients: experience from the first Italian wave. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	7
190	Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients. <i>Pharmaceutics</i> , 2022, 14, 1828.	2.0	0
191	miR-142 Targets TIM-1 in Human Endothelial Cells: Potential Implications for Stroke, COVID-19, Zika, Ebola, Dengue, and Other Viral Infections. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10242.	1.8	11
192	Von Willebrand Factor Multimer Analysis and Classification: A Comprehensive Review and Updates. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	2
193	Obesity and coronavirus disease 2019. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 207-218.	1.0	3
194	Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality. <i>Life Sciences</i> , 2022, 310, 121018.	2.0	13
195	Rethinking sepsis after a two-year battle with COVID-19. , 2022, 19, 1317-1318.		5
196	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10

#	ARTICLE	IF	CITATIONS
197	Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
199	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <i>Life</i> , 2022, 12, 1605.	1.1	12
200	Hyperresponsive Platelets and a Reduced Platelet Granule Release Capacity Are Associated with Severity and Mortality in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 2001-2010.	1.8	7
201	Platelet-Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	9
202	Effect of stimulated platelets in COVID-19 thrombosis: Role of alpha7 nicotinic acetylcholine receptor. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
203	Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF- κ B signaling pathways. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
204	Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 82-87.	0.1	0
205	COVID-19 and antiphospholipid antibodies. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101402.	0.7	12
206	Acute Respiratory Distress Syndrome and the Use of Inhaled Pulmonary Vasodilators in the COVID-19 Era: A Narrative Review. <i>Life</i> , 2022, 12, 1766.	1.1	5
207	The Effect of Reduced Oxygen Saturation on Retinal Microvascularization in COVID-19 Patients with Bilateral Pneumonia Based on Optical Coherence Tomography Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1824.	1.1	2
208	Extended coagulation profile of children with Long Covid: a prospective study. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
209	Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment. <i>Cell Reports Medicine</i> , 2022, 3, 100833.	3.3	17
210	Platelet in thrombo-inflammation: Unraveling new therapeutic targets. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
211	Recovery of systemic hyperinflammation in patients with severe SARS-CoV-2 infection. <i>Biomarkers</i> , 2023, 28, 97-110.	0.9	1
212	SARS-CoV-2 Infection and Increased Risk for Pediatric Stroke. <i>Pediatric Neurology</i> , 2023, 142, 89-94.	1.0	3
213	Cell-Based Drug Delivery Systems Participate in the Cancer Immunity Cycle for Improved Cancer Immunotherapy. <i>Small</i> , 2023, 19, .	5.2	10
215	Platelets in COVID-19 disease: friend, foe, or both?. <i>Pharmacological Reports</i> , 2022, 74, 1182-1197.	1.5	2
216	Corona virus disease 2019-associated liver injury in cold regions. <i>Frigid Zone Medicine</i> , 2022, 2, 193-199.	0.2	0

#	ARTICLE	IF	CITATIONS
217	Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Caseâ€“Control Study. <i>Biomedicines</i> , 2022, 10, 3135.	1.4	2
218	A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. <i>PLoS ONE</i> , 2023, 18, e0280079.	1.1	0
219	Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on â€œVolod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>J. Clin. Med.</i> 2022, 11, 860â€œ. <i>Journal of Clinical Medicine</i> , 2023, 12, 478.	1.0	1
221	Systematic Review of Endocan as a Potential Biomarker of COVID-19. <i>Angiology</i> , 0, , 000331972311529.	0.8	8
222	Extracellular Vesicles: New Players in the Mechanisms of Sepsis- and COVID-19-Related Thromboinflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1920.	1.8	4
223	COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells. <i>Antioxidants</i> , 2023, 12, 326.	2.2	18
224	Host Recovery from Respiratory Viral Infection. <i>Annual Review of Immunology</i> , 2023, 41, 277-300.	9.5	10
225	â€œThromboinflammation in COVID-19: can Î±2-macroglobulin help to control the fire?â€œ Comment from Seitz etAal.. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 704-705.	1.9	0
226	Masticatory Functionality in Post-Acute-COVID-Syndrome (PACS) Patients with and without Sarcopenia. <i>Oral</i> , 2023, 3, 77-91.	0.6	0
227	Humoral immunity and thrombosis in COVID-19. , 2023, , 375-392.		0
228	Realâ€“time intelligent classification of <scp>COVID</scp> â€œ19 and thrombosis via massive imageâ€“based analysis of platelet aggregates. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 0, , .	1.1	1
229	Neurological consequences of SARS-CoV-2 infections in the pediatric population. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	6
230	Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation. <i>Archives of Cardiovascular Diseases</i> , 2023, 116, 183-191.	0.7	4
231	Hyperinflammatory Response in COVID-19: A Systematic Review. <i>Viruses</i> , 2023, 15, 553.	1.5	20
232	Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches. <i>Vaccines</i> , 2023, 11, 489.	2.1	3
233	Predictors and outcomes of acute pulmonary embolism in COVID-19; insights from US National COVID cohort collaborative. <i>Respiratory Research</i> , 2023, 24, .	1.4	10
234	Platelets and COVID-19. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 53-57.	0.1	0
235	Can Platelet Mass Index Be Used as a Prognostic Marker in Children Diagnosed with Multisystem Inflammatory Syndrome Associated with Coronavirus?. <i>Turkish Journal of Pediatric Disease</i> , 0, , 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
236	Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712.	1.1	2
237	Severe Acute Respiratory Syndrome Coronavirus 2 Vasculopathy in a Syrian Golden Hamster Model. <i>American Journal of Pathology</i> , 2023, 193, 690-701.	1.9	3
238	Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses. <i>Blood Reviews</i> , 2023, 60, 101075.	2.8	10
239	TNF/iNOS/NO pathway mediates host susceptibility to endothelial-dependent circulatory failure and death induced by betacoronavirus infection. <i>Clinical Science</i> , 2023, 137, 543-559.	1.8	4
240	Long-Term Effect of SARS-CoV-2 Infection on the Retinal and Choroidal Microvasculature. <i>Journal of Clinical Medicine</i> , 2023, 12, 2528.	1.0	4
241	SARS-CoV-2 RBD and Its Variants Can Induce Platelet Activation and Clearance: Implications for Antibody Therapy and Vaccinations against COVID-19. <i>Research</i> , 2023, 6, .	2.8	3
242	The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6709.	1.8	2
243	Identification the genetic influence of SARS-CoV-2 infections on IgA nephropathy based on bioinformatics method.. <i>Kidney and Blood Pressure Research</i> , 0, , .	0.9	0
244	Gut microbiome alterations in patients with COVID-19-related coagulopathy. <i>Annals of Hematology</i> , 0, , .	0.8	0
245	COVID-19, Blood Lipid Changes, and Thrombosis. <i>Biomedicines</i> , 2023, 11, 1181.	1.4	2
246	Cardiovascular Manifestations of the Long COVID Syndrome. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	3
247	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
248	Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7593.	1.8	2
302	Panendothelitis Due to the SARS COV 2 Infection: Consequences on Hypertension and Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 181-227.	0.1	0